CureVac N.V. (CVAC)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CureVac N.V. (CVAC) trades at $4.66 with AI Score 71/100 (Buy). CureVac N. V. is a clinical-stage biopharmaceutical company pioneering mRNA-based medicines. Market cap: 2B, Sector: Healthcare.
Last analyzed: Feb 8, 2026CureVac N.V. (CVAC) Healthcare & Pipeline Overview
CureVac N.V. is revolutionizing medicine with its mRNA technology, developing innovative vaccines and immunotherapies. With a strong profit margin of 37.9% and a gross margin of 95.0%, CureVac is poised to capitalize on the growing demand for advanced biopharmaceutical solutions, targeting significant unmet medical needs.
Investment Thesis
CureVac N.V. presents a notable research candidate due to its innovative mRNA technology platform and diverse pipeline of vaccine and immunotherapy candidates. The company's strong gross margin of 95.0% highlights the potential for high profitability as its products advance through clinical trials and reach commercialization. Key value drivers include the successful development and regulatory approval of its mRNA-based vaccines for infectious diseases such as SARS-CoV-2, influenza, and rabies. Upcoming catalysts include the progression of CV2CoV and CV8102 through clinical trials, with potential data readouts in the next 12-24 months. With a market capitalization of $1.05 billion and a P/E ratio of 4.58, CureVac offers an attractive entry point for investors seeking exposure to the high-growth biotechnology sector.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $1.05B reflects investor confidence in CureVac's mRNA technology and pipeline.
- Profit Margin of 37.9% indicates strong potential for profitability upon commercialization of its vaccine and immunotherapy candidates.
- Gross Margin of 95.0% showcases the high value and efficiency of CureVac's mRNA-based platform.
- Beta of 1.84 suggests higher volatility compared to the market, offering potential for significant gains but also increased risk.
- Focus on mRNA technology positions CureVac at the forefront of a rapidly evolving field with broad applications in vaccines and therapeutics.
Competitors & Peers
Strengths
- Proprietary mRNA technology platform.
- Diverse pipeline of vaccine and immunotherapy candidates.
- Strong gross margin of 95.0%.
- Experienced management team.
Weaknesses
- Clinical-stage company with no currently approved products.
- High R&D costs and long development timelines.
- Dependence on successful clinical trial outcomes.
- Intense competition in the biotechnology industry.
Catalysts
- Clinical trial data readouts for CV2CoV (SARS-CoV-2 vaccine) and CV8102 (cancer immunotherapy).
- Potential regulatory approvals for vaccine candidates in key markets.
- New strategic partnerships and collaborations to expand pipeline and market reach.
- Expansion of manufacturing capacity to meet future demand.
Risks
- Clinical trial failures or delays.
- Regulatory setbacks or rejection of product applications.
- Competition from other biotechnology and pharmaceutical companies.
- Intellectual property disputes and challenges.
- Dependence on key personnel and scientific advisors.
Growth Opportunities
- Expansion of mRNA Vaccine Pipeline: CureVac has the opportunity to expand its mRNA vaccine pipeline beyond its current targets, including SARS-CoV-2, influenza, and rabies. The global vaccine market is projected to reach $90 billion by 2028, driven by increasing awareness of preventative healthcare and the emergence of new infectious diseases. By leveraging its mRNA technology platform, CureVac can rapidly develop and commercialize vaccines for a wide range of diseases, capturing a significant share of this growing market. Timeline: Ongoing.
- Advancement of Cancer Immunotherapy Programs: CureVac's CV8102 cancer immunotherapy program holds significant promise for treating various types of cancer, including cutaneous melanoma and adenoidcystic carcinoma. The global cancer immunotherapy market is expected to reach $126.9 billion by 2030. Successful clinical trials and regulatory approval of CV8102 could position CureVac as a leader in the cancer immunotherapy space, driving substantial revenue growth. Timeline: Ongoing.
- Strategic Partnerships and Collaborations: CureVac can accelerate its growth by forming strategic partnerships and collaborations with other pharmaceutical companies, research institutions, and government agencies. These partnerships can provide access to new technologies, funding, and expertise, enabling CureVac to expand its pipeline and accelerate the development and commercialization of its products. Timeline: Ongoing.
- Geographic Expansion: CureVac has the opportunity to expand its geographic presence beyond Europe and enter new markets, such as North America and Asia. These markets offer significant growth potential due to their large populations and increasing healthcare spending. By establishing a presence in these regions, CureVac can increase its revenue and market share. Timeline: Ongoing.
- Personalized Medicine Applications: CureVac's mRNA technology platform can be used to develop personalized medicine applications, tailoring treatments to individual patients based on their genetic profiles and disease characteristics. The personalized medicine market is projected to reach $3.18 trillion by 2033. By leveraging its expertise in mRNA technology, CureVac can develop personalized cancer vaccines and other therapies, addressing the unmet needs of patients with complex diseases. Timeline: Ongoing.
Opportunities
- Expansion of mRNA vaccine pipeline.
- Advancement of cancer immunotherapy programs.
- Strategic partnerships and collaborations.
- Geographic expansion into new markets.
Threats
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from established pharmaceutical companies.
- Intellectual property challenges.
Competitive Advantages
- Proprietary mRNA technology platform with significant intellectual property protection.
- Extensive experience and expertise in mRNA vaccine and immunotherapy development.
- Strong relationships with leading researchers and institutions.
- Established manufacturing capabilities for mRNA-based products.
About CVAC
Founded in 2000 and headquartered in Tübingen, Germany, CureVac N.V. is a clinical-stage biopharmaceutical company at the forefront of messenger ribonucleic acid (mRNA) technology. The company is dedicated to developing transformative medicines across a range of therapeutic areas, primarily focusing on prophylactic vaccines and RNA-based cancer immunotherapies. CureVac's pioneering work in mRNA technology has led to a diverse pipeline of vaccine candidates, including CV2CoV, currently in Phase 1 clinical trials for SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine that has completed Phase 1 clinical trials for rabies virus glycoprotein; and CVSQIV, in Phase 1 clinical trials against influenza. Beyond these, CureVac is also developing vaccines for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza. In the realm of cancer immunotherapy, CureVac is advancing CV8102, which is in Phase 1 clinical trials for treating cutaneous melanoma, adenoidcystic carcinoma, and squamous cell cancer of the skin, head, and neck. CureVac's strategic focus on mRNA technology positions it as a key player in the future of medicine, with the potential to address a wide array of infectious diseases and cancers.
What They Do
- Develop mRNA-based prophylactic vaccines for infectious diseases.
- Create RNA-based cancer immunotherapies.
- Conduct clinical trials to evaluate the safety and efficacy of their vaccine and immunotherapy candidates.
- Research and develop new mRNA-based technologies for therapeutic applications.
- Seek regulatory approval for their products from health authorities worldwide.
- Manufacture and commercialize their approved products.
- Forge strategic partnerships to expand their pipeline and market reach.
Business Model
- Develop and out-license mRNA-based vaccine and immunotherapy technologies.
- Generate revenue through research grants and collaborations.
- Commercialize approved products through direct sales and distribution networks.
- Receive milestone payments and royalties from partnered programs.
Industry Context
CureVac operates within the dynamic and competitive biotechnology industry, which is experiencing rapid growth driven by technological advancements and increasing demand for innovative therapies. The mRNA technology space, in particular, has gained significant attention due to its potential for rapid vaccine development and personalized medicine. CureVac competes with established pharmaceutical companies and other biotech firms, including Alnylam Pharmaceuticals (AMLX), Elevar Therapeutics (ELVN), Immatics (IMTX), and Inhibrx (INBX), all vying for market share in the vaccine and immunotherapy markets. The industry is characterized by high R&D costs, long development timelines, and stringent regulatory requirements.
Key Customers
- Patients seeking preventative vaccines for infectious diseases.
- Patients with cancer seeking innovative immunotherapies.
- Pharmaceutical companies licensing CureVac's mRNA technology.
- Government agencies and public health organizations.
Financials
Chart & Info
CureVac N.V. (CVAC) stock price: $4.66 (-0.01, -0.21%)
Latest News
No recent news available for CVAC.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CVAC.
Price Targets
Wall Street price target analysis for CVAC.
MoonshotScore
What does this score mean?
The MoonshotScore rates CVAC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
CureVac N.V. Healthcare Stock: Key Questions Answered
What does CureVac N.V. do?
CureVac N.V. is a biopharmaceutical company specializing in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Their primary focus is on creating prophylactic vaccines for infectious diseases and RNA-based cancer immunotherapies. The company's mRNA technology platform allows for the rapid development of vaccine candidates and personalized therapies, addressing a wide range of unmet medical needs. CureVac is currently conducting clinical trials to evaluate the safety and efficacy of its product candidates, with the goal of obtaining regulatory approval and commercializing its innovative medicines.
Is CVAC stock worth researching?
CVAC stock presents a speculative investment opportunity with high potential upside and significant risks. The company's innovative mRNA technology and diverse pipeline of vaccine and immunotherapy candidates offer compelling growth prospects. However, as a clinical-stage company with no currently approved products, CureVac's success depends on the successful completion of clinical trials and regulatory approvals. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing in CVAC stock. The company's strong gross margin of 95.0% suggests the potential for high profitability if its products reach the market.
What are the main risks for CVAC?
CureVac faces several key risks, including the potential for clinical trial failures, regulatory setbacks, and intense competition in the biotechnology industry. The development of new medicines is inherently risky, and there is no guarantee that CureVac's vaccine and immunotherapy candidates will be proven safe and effective. Regulatory approval processes can be lengthy and unpredictable, and delays or rejections could significantly impact the company's prospects. CureVac also faces competition from larger, more established pharmaceutical companies with greater resources and expertise. Intellectual property disputes and challenges also pose a risk to the company's proprietary technology.
What are the key factors to evaluate for CVAC?
CureVac N.V. (CVAC) currently holds an AI score of 71/100, indicating high score. The stock trades at a P/E of 7.1x, below the S&P 500 average (~20-25x), potentially signaling value. Key strength: Proprietary mRNA technology platform. Primary risk to monitor: Clinical trial failures or delays. This is not financial advice.
How frequently does CVAC data refresh on this page?
CVAC prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CVAC's recent stock price performance?
Recent price movement in CureVac N.V. (CVAC) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary mRNA technology platform. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CVAC overvalued or undervalued right now?
Determining whether CureVac N.V. (CVAC) is overvalued or undervalued requires examining multiple metrics. Its P/E ratio is 7.1. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CVAC?
Before investing in CureVac N.V. (CVAC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Investment in biotechnology companies is inherently risky.